Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer

Lancet

Volumn 352, Issue 9138, 1998, Pages 1407-1412

  Rougier, Philippe ^a,l   Van Cutsem, Eric ^b   Bajetta, Emilio ^c   Niederle, Norbert ^d   Possinger, Kurt ^e   Labianca, Roberto ^f   Navarro, Matilde ^g   Morant, Rudolf ^h   Bleiberg, Harry ⁱ   Wils, Jacques ^j   Awad, Lucile ^k   Herait, Patrice ^k   Jacques, Christian ^k  

^a INSTITUT GUSTAVE ROUSSY   (France)

^b UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^c NATIONAL CANCER INSTITUTE   (Italy)

^d KLINIKUM LEVERKUSEN   (Germany)

^e Medizinische Klinik II   (Germany)

^f SAN CARLO BORROMEO HOSPITAL   (Italy)

^g CATALAN INSTITUTE OF ONCOLOGY   (Spain)

^h CANTONAL HOSPITAL ST GALLEN   (Switzerland)

ⁱ JULES BORDET INSTITUTE   (Belgium)

^j LAURENTIUS HOSPITAL   (Netherlands)

^k SANOFI   (France)

^l HÔPITAL AMBROISE PARÉ   (France)

more..

Author keywords

[No Author keywords available]

Indexed keywords

FLUOROURACIL; FOLINIC ACID; IRINOTECAN;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER SURVIVAL; CLINICAL TRIAL; COLORECTAL CANCER; CONTINUOUS INFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG EFFICACY; DRUG TOLERABILITY; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MALE; METASTASIS; MULTICENTER STUDY; NAUSEA; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SURVIVAL TIME; VOMITING;

EID: 0032585197     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(98)03085-2     Document Type: Article

References (23)

1. 1 Cunningham D, Findlay M. The chemotherapy of colon cancer can no longer be ignored. Eur J Cancer 1996; 29A: 2077-79.
2. 2 Nordic Gastrointestinal Tumor Adjuvant Therapy Group. Expectancy or primary chemotherapy in patients with advanced asymptomatic colorectal cancer: a randomised trial. J Clin Oncol 1993; 10: 904-11.
3. 3 Scheithauer W, Rosen H, Kornek G-V, et al. Randomised comparison of combination chemotherapy plus supportive care with supportive care alone in patients with metastatic colorectal cancer. BMJ 1993; 306: 752-55.
4. 4 Weh MJ, Wilke HJ, Dierlamm J, et al. Weekly therapy with folinic acid (FA) and high-dose fluorouracil (5-FU) 24 hour infusion in pretreated patients with metastatic colorectal carcinoma. Ann Oncol 1994; 5: 233-37.
5. 5 Jäger E, Klein O, Wächter B, et al. High-dose 5-fluorouracil (5FU) and folinic acid in advanced colorectal cancer resistant to standard dose 5FU treatment: results of a phase II study. Eur J Cancer 1995; 31A: 10 (abstr).
6. 6 Schmoll HJ. Is there a second line therapy in colorectal cancer? Vienna: ESMO Educational Books, 1996.
7. 7 Findlay M, Hill A, Cunningham D, et al. Protracted venous infusion of 5-fluorouracil and α-interferon in advanced and refractory colorectal cancer. Ann Oncol 1994; 5: 239-43.
8. 8 Izzo J, Zarba J, Rougier P, et al. Low-dose 5-FU continuous infusion (FuCI) in advanced colorectal cancer (ACC): clinical evidence for reversal of acquired-intrinsic resistance to 5-FU or 5-FU folinic acid (FuFo). Proc AACR 1992; 33: 217.
9. 9 Sobrero AF, Aschele C, Bertino JR. Fluorouracil in colorectal cancer - a tale of two drugs: implications for biochemical modulation. J Clin Oncol 1997; 15: 368-81.
10. 10 de Gramont A, Bosset J-F, Milan C, et al. Randomized trial comparing monthly low-dose leucovorin and fluorouracil bolus with bimonthly high-dose leucovorin and fluorouracil bolus plus continuous infusion for advanced colorectal cancer: a French Intergroup Study. J Clin Oncol 1997; 15: 808-15.
11. 11 Hansen R, Quebbeman E, Ausman R, et al. Continuous systemic 5-fluorouracil infusion in advanced colorectal cancer: results in 91 patients. J Surg Oncol 1989; 40: 177-81.
12. 12 Ducreux M, Rougier Ph, Voni R, et al. Lack of relationship between plasma concentration and clinical parameters in patients with metastatic colorectal cancer (MCRC) treated with prolonged infusion of 5-fluorouracil (PIF) and oral leucovorin. Proc AACR 1996; 37: 408 (abstr).
13. 13 Ardalan B, Chua L, Tiang E-M, et al. A phase II study of weekly 24-hour infusion with high-dose fluorouracil with leucovorin in colorectal carcinoma. J Clin Oncol 1991; 9: 625-30.
14. 14 Van Cutsem E, Rougier Ph, Droz JP, et al. Clinical benefit of irinotecan (CPT-Il) in metastatic colorectal cancer (CRC) resistant to 5-FU. Proc ASCO 1997; 16: 268a (abstr).
15. 15 Rougier P, Bugat R, Douillard JY, et al. Phase II study of irinotecan in the treatment of advanced colorectal cancer in chemotherapy-naïve patients and patients pretreated with fluorouracil-based chemotherapy. J Clin Oncol 1997; 15: 251-60.
16. 16 Von Hoff DD, Rothenberg ML, Pilot HC, et al. Irinotecan (CPT-11) therapy for patients with previously treated metastatic colorectal cancer (CRC): overall results of FDA-reviewed pivotal US clinical trials. Proc ASCO 1997; 16: 228a (abstr).
17. 17 Pocock SJ, Simon R. Sequential treatment assignment with balancing of prognostic factors in the controlled clinical trial. Biometrics 1975; 31: 103-05.
18. 18 Aaranson NK, Ahmedzai S, Bergman B, et al. The European Organization for Research and Treatment of cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 1993; 85: 365-76.
19. 19 Freedman LS. Tables of the number of patients required in clinical trials using the logrank test. Stat Med 1982; 1: 121-29.
20. 20 Rougier P, Milan C, Lazorthes F, et al. Prospective study of prognostic factors in patients with unresected hepatic metastases from colorectal cancer. Br J Surg 1995; 82: 1397-1400.
21. 21 Kemeny N, Niedzwiecki D, Shurgot B, et al. Prognostic variables in patients with hepatic metastases from colorectal cancer. Cancer 1989; 63: 742-47.
22. 22 Pilot HC, Wender DB, O'Connell MJ, et al. Phase II trial of irinotecan in patients with metastatic colorectal carcinoma. J Clin Oncol 1997; 15: 2910-19.
23. 23 Diehr P, Patrick D, Hedrick S, et al. Including deaths when measuring Health Status over time. Med Care 1995; 33: AS164-72.